18480038. ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
Contents
- 1 ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER
Organization Name
Arizona Board of Regents on Behalf of Arizona State University
Inventor(s)
Rachael Sirianni of San Francisco CA (US)
Rebecca Cook of Scottsdale AZ (US)
Joseph Blattman of Scottsdale AZ (US)
ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 18480038 titled 'ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER
Simplified Explanation
The patent application describes compositions and methods for treating cancer using a polypeptide with two domains, one binding to CD3 and the other to cancer cells.
- The polypeptide has at least two domains: one binding to CD3 and the other to cancer cells.
- The method involves administering the polypeptide to a subject to treat cancer effectively.
Potential Applications
The technology can be applied in the field of cancer treatment and immunotherapy.
Problems Solved
This technology addresses the challenge of targeting cancer cells specifically while minimizing damage to healthy cells.
Benefits
The technology offers a targeted approach to cancer treatment, potentially reducing side effects associated with traditional therapies.
Potential Commercial Applications
The technology could be used in the development of novel cancer therapies, leading to improved patient outcomes.
Possible Prior Art
Prior art may include similar compositions and methods for targeting cancer cells using polypeptides with specific binding domains.
Unanswered Questions
How does the polypeptide specifically target cancer cells without affecting healthy cells?
The specificity of the polypeptide's binding domains to CD3 and cancer cells needs to be further elucidated through additional studies.
What is the long-term efficacy and safety profile of the polypeptide in treating different types of cancer?
Long-term studies are needed to assess the durability of the treatment response and potential adverse effects in diverse patient populations.
Original Abstract Submitted
Disclosed herein are compositions comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell. Also disclosed herein are methods of treating cancer in a subject, comprising: providing a composition comprising a polypeptide with at least two domains, wherein the first domain is capable of binding CD3 and the second domain is capable of binding to a cancer cell; and treating the cancer by administering a therapeutically effective dosage of the composition to the subject.
